Adarx Pharmaceuticals, Inc.
Clinical trials sponsored by Adarx Pharmaceuticals, Inc., explained in plain language.
-
New drug trial aims to control kidney disease in chinese patients
Disease control Recruiting nowThis study tests a new drug called ADX-038 in 30 Chinese adults with kidney diseases caused by the immune system attacking the kidneys (IgA nephropathy, C3G, or IC-MPGN). The goal is to see if the drug is safe and can help control the disease, either alone or with another medicat…
Phase: PHASE2 • Sponsor: ADARx Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
New hope for HAE patients: extension study tests long-term attack prevention
Disease control Recruiting nowThis study is for people with hereditary angioedema (HAE) who finished a previous phase 3 trial of ADX-324. It aims to see if the drug is safe and can prevent swelling attacks over a longer period. About 90 participants will receive additional doses of ADX-324 and be monitored fo…
Phase: PHASE3 • Sponsor: ADARx Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 14, 2026 12:04 UTC
-
New drug ADX-038 aims to control rare kidney diseases
Disease control Recruiting nowThis study tests a new drug called ADX-038 in 45 adults with kidney diseases caused by an overactive complement system (part of the immune system), including IgA nephropathy and C3G. The goal is to see if the drug is safe and can help control the disease. Participants must have a…
Phase: PHASE2 • Sponsor: ADARx Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 12, 2026 13:44 UTC